Rebecca Byam, Chief Financial Officer at HCW Biologics Inc. (HCWB), bought 5,000 shares at $1.95 ($10K) on 2023-09-06, disclosed to the SEC on 2023-09-07.
Open-market purchase of $10k HCWB by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| HCWB | BUY | 2023-09-15 | $11K | — | Filing → |
| HCWB | BUY | 2023-09-13 | $21K | — | Filing → |
| HCWB | BUY | 2023-09-08 | $20K | — | Filing → |